VHH Antibody Applications
From Robust Tools to Complex Therapeutics
Versatile formats and validated workflows for CAR-T, Bi-specifics, ADCs, and more. See Applications
Isogenica’s synthetic, humanized VHH antibodies offer flexible, high-performance solutions across a growing range of therapeutic and diagnostic applications. Their small size, stability, and binding precision make them ideal for applications where conventional antibodies fall short – from CAR-T and Bi-specifics to ADCs, intracellular targets, and robust tools.
Backed by modular technologies and a peer-level partnership model, Isogenica helps biotech teams design, screen, and optimize candidates faster and with greater confidence.
Antibody Conjugate and ADC Applications
VHHs are versatile can be used to target any number of payloads to a biological target – this includes small molecules (ADC), oligonucleotides (AOC), radionuclides (ARC), as well as large carriers such as LNPs or viral particles. Our suite of conjugation handles can be included from the very earliest stages of VHH discovery.
VHH Antibodies for Difficult Targets
GPCRs, ion channels, and multipass transmembrane proteins are among the most therapeutically relevant targets and the most likely to defeat conventional discovery campaigns. Isogenica screens multiple target materials and presentations in parallel, identifying viable discovery paths early and concentrating investment where biology and assay performance align.
Bi-Specific Antibodies
The small size and modularity of VHHs enable versatile bi– or multi–specific designs where you control valency, linker length, and more. Isogenica’s platform supports parallel discovery of high-affinity binders for dual-target formats, with early data to guide pairing and optimization.
CAR-T and Cell Therapy
VHHs offer a compact, stable, and clinically validated alternative to scFvs in CAR-T constructs – reducing aggregation and T-cell exhaustion while improving expression and manufacturability. Isogenica’s synthetic libraries provide high-specificity VHHs suitable for targeting tumor-associated antigens.
Intracellular Targets and Protein Degradation
Advances in genetic delivery have opened the intracellular target space to antibody-based therapeutics and VHHs are well positioned to exploit it. Their short gene length preserves vector capacity, and their stability in the cytoplasmic environment supports reliable intracellular expression for intrabody and bioPROTAC programmes.
Agonists & Antagonists
VHHs can act as direct modulators of target activity, with high specificity and adaptable valency. Isogenica’s partnership with Axxam further supports agonist discovery through early high-throughput screening in functional cell assays.
Radiopharma and Molecular Imaging
Conventional antibodies clear slowly, limiting signal-to-noise and prolonging patient exposure to radioactive isotopes. VHHs clear rapidly via the kidneys, enable high-contrast PET/SPECT imaging within hours of injection, and retain stability under radiolabelling conditions, supporting both diagnostic and theranostic applications.
Algorithm-Driven VHH Discovery
Standard Sanger sequencing recovers only the most abundant clones, leaving rare binders, often those with the most valuable properties, undetected. Isogenica combines NGS analysis with CIS Display to build sequence datasets that expose what conventional screening misses, and that are structured for AI/ML-guided make–test–learn cycles.
FAQs
Which VHH applications are you most commonly supporting today?
Demand is strongest in ADC/AOC programmes, CNS and delivery applications, multispecific immune engagement, and difficult or membrane-associated targets.
Are your libraries suitable for GPCRs and ion channels?
Yes. Our libraries and CIS Display™ platform are well suited to membrane proteins and conformationally dynamic targets.
Do you provide cross-reactive VHHs for preclinical species?
Yes. Cross-species binding can be selected or engineered using orthologue antigens and guided maturation.
Can a single VHH discovery programme support multiple downstream applications?
Yes. VHHs can often be reformatted to support multiple modalities, depending on target biology.
Work with us
By partnering with our expert team, you’ll not only benefit from access to our state-of-the-art technology and expertise but also the perks of how we like to work with others. From start to finish we become an extended part of your team, keeping you updated and informed regularly on our progress. With our groundbreaking technology and expert guidance, Isogenica helps small to mid-sized biotech companies bring novel therapies to market faster— cutting typical discovery timelines in half by accelerating lead selection and reducing follow-on engineering requirements. Talk to us today and find out how we can accelerate your VHH discovery project.